Jun. 27 at 2:54 PM
$BTSG surging ahead — time to buy the dip? 🚀
🔹 33% growth in infusion & specialty pharmacy segment in Q1 2025
🔹 Raised 2025 guidance with revenue expected between
$12B-
$12.5B
🔹 Trading at an attractive forward P/S of 0.31x, relative to
$OPCH’s 0.90x
Discover why BrightSpring is a Zacks Rank #2 (Buy) while OPCH holds at #3 👇 https://www.zacks.com/commentary/2555130/btsg-vs-opch-which-home-infusion-stock-is-a-better-buy-now?cid=sm-stocktwits-2-2555130-body-315&ADID=SYND_STOCKTWITS_TWEET_2_2555130_BODY_315